STUDresearch · Peptide
Enicepatide
Also known as
CT-388 · CT388 · RO7795068 · RG6640 · Roche / Carmot dual GLP-1/GIP
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Subcutaneous (weekly trials)
Metabolic / GLP-1 class
Systemic once-weekly biased dual GLP-1/GIP agonist (Carmot → Roche).
What people say
Enicepatide, formerly CT-388 or RO7795068, is Roche's investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist. It is not approved, and the public evidence is dominated by early clinical trials and company disclosures.
Doses people talk about
These are investigational trial cohorts with controlled escalation, not a consumer label, cross-drug conversion, or personal progression.
How it may feel
The checked community threads contain trial-result discussion but no substantive first-person use diary. Phase II reported mostly mild-to-moderate gastrointestinal adverse events, but this does not supply a dependable felt timeline.
Phase II obesity target doses4 / 8 / 12 / 16 / 24 mg once weekly
Five subcutaneous groups over 48 weeks with different up-titration schemes.
Phase I single-dose cohorts0.5–7.5 mg once
Single-ascending-dose safety and PK context.
Phase I repeated-dose cohorts5–12 mg once weekly for four doses
Multiple-ascending-dose safety and PK context; later PK follow-up also examined repeated 8, 12 and 22 mg exposures.
Half-life & effect duration
- Half-life in the body
- Week-12 study groupAbout 134.6 hours
- Week-24 study groupsAbout 151.2 hours
- Felt duration people report
- Felt durationNo consistent firsthand window reported
Cycles people discuss
Phase II studied weekly treatment for 48 weeks; Phase III is a development program, not a consumer cycle.
Timing
Repeated-dose Phase I data reported a mean terminal half-life of about 135–151 hours and median Tmax of 24 hours. A subjective onset or per-dose felt duration has not been established.
Stacks
Phase II evaluated enicepatide as the study drug; company material discusses combinations such as petrelintide as future development, not established user stacks.
Watch for
GI class: Mild–moderate nausea/vomit/diarrhea. AE discontinuation 5.9% vs 1.3% placebo in the 48-week package.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
Phase I supplemental material reported mean terminal half-life values from 134.6 to 151.2 hours, with median Tmax of 24 hours.
The lower value was reported at week 12 in an 8 mg group and the higher value at week 24 in pooled 12/22 mg groups.
Small early-phase cohorts, pooled higher-dose groups, investigational formulations, and repeated-dose conditions limit generalization; the range is not a dosing recommendation.
- Safety, pharmacokinetics and pharmacodynamics of CT-388 — EASD 2024 supplemental material (opens in a new tab)Repeated-dose PK tables report mean terminal half-life of 134.6 hours at week 12 for 8 mg and 151.2 hours at week 24 for pooled 12/22 mg groups, with median Tmax of 24 hours.Sponsor-hosted early-phase supplemental material with small cohorts and pooled groups; not a marketed-product label.
Felt duration people report
A dependable felt-duration window was not established by the checked trial disclosures or community discussion.
Company material reports aggregate adverse events and weight change, while community threads mainly compare headline trial results with other drugs.
Aggregate trial safety tables do not describe a per-dose felt clock, and community posts lacked verified participant diaries.
- Roche's enicepatide achieves up to 22.5% placebo-adjusted weight loss in Phase II (opens in a new tab)Top-line Phase II disclosure describes five cohorts, 48 weeks, highest 24 mg dose, 22.5% efficacy-estimand and 18.3% treatment-estimand placebo-adjusted weight loss, no plateau, mostly mild-to-moderate GI events, and discontinuation rates.Company top-line release, not a peer-reviewed full results paper; estimands and titration cohorts require careful distinction.
- Roche investor event at ADA 2026: enicepatide Phase II results (opens in a new tab)Slides describe 467 randomized participants, 4/8/12/16/24 mg weekly subcutaneous target doses, up-titration through 27 weeks, maintenance through week 48, five-week follow-up, weight estimands, and dose-group adverse-event tables.Sponsor slide deck with top-line analyses rather than peer-reviewed publication; group-specific titration and estimand definitions constrain comparisons.
- CT-388 Roche (opens in a new tab)Thread asks whether anyone is participating in Phase III; the inspected replies do not provide a substantive verified use report.Sparse anonymous discussion with no verified trial participation or product identity.
- Roche Phase 2 CT-388 discussion (opens in a new tab)Commenters compare Roche's Phase II headline with tirzepatide, retatrutide and cagrilintide/semaglutide; some initially confuse raw and placebo-adjusted estimates, and no verified participant diary appears.Investor-oriented anonymous discussion, headline interpretation errors, no product verification, and no first-person treatment evidence.
Other context in this card
- NCT06525935: Study of CT-388 in participants with overweight or obesity (opens in a new tab)Registry identifies the completed Phase II study, 469 enrollment, subcutaneous route, and 48-week design; posted registry did not supply full peer-reviewed results.Registry record and sponsor-entered fields; enrollment differs slightly from analyzed slide populations and results publication remains limited.
- NCT04838405: Study of CT-388 in overweight and obese participants and healthy participants (opens in a new tab)Registry identifies the completed Phase I subcutaneous study and 129 enrolled participants.Registry overview does not alone provide all dose-level PK estimates or subjective experience data.
What people say
- Class dual read: Forums file it next to Zepbound, not Wegovy. Cross-trial, not a head-to-head. forum
- Phase 2 48-week scale: Placebo-adjusted ~18–22.5% depending on estimand; Reuters ~22.7% at 48 weeks. 24 mg had not plateaued — Roche’s “more to go” slide. trial
- Phase 1 (4 weeks): About −4.7% to −8.0% vs −0.5% placebo across 5–12 mg weekly. trial
- Combo optionality: Mid-2026 plan to pair with petrelintide. That is a press-release stack. trial
Doses people talk about
- Do not copy tirz 2.5→15 onto CT-388 mg. Different analog. forum
- No label. forum
- Phase 1: Single 0.5–7.5 mg; weekly 5–12 mg × 4. trial
- Phase 2 obesity: Five weekly SC doses from 4 mg to 24 mg. trial
How it may feel
- Direct-experience gap: The checked community threads discuss trial results and comparisons with tirzepatide, but do not provide a substantive first-person enicepatide use diary. Subjective effects should not be imported from another drug. forum
- Jefferies-style social take: “Modestly worse sides than what’s already on the market, late.” That is the mood, not a pin diary. forum
- Trial tolerability: Gastrointestinal adverse events were reported across dose groups during the 48-week Phase II study and were mostly mild to moderate; the public material does not establish a universal week-by-week felt pattern. trial
- Months 3–12: Phase 2 loss still climbing at 48 weeks on 24 mg. trial
Cycles people discuss
- Weekly for 48 weeks in Phase 2. trial
- Phase 3 Enith is the next calendar, not a consumer cycle. trial
Timing
- Missed week: No diary lore. Class weekly logic. forum
- Phase I PK: After repeated weekly subcutaneous dosing, mean terminal half-life was reported as 134.6 hours at week 12 in the 8 mg group and 151.2 hours at week 24 in pooled 12/22 mg groups; median Tmax was 24 hours. trial
More on what it is
- Why people talk about it: Reuters/ADA 2026: ~22.7% at 48 weeks, 4–24 mg arms, no plateau at 24 mg. r/Zepbound treated it as “another tirz, a bit later, GI maybe a hair worse.” forum
- Feel-log honesty: Almost no “I pinned CT-388” diary layer. This card is trial-thread + class GLP/GIP feel. forum
- Not the same as: Tirzepatide. Petrelintide (Roche’s *other* obesity shot — amylin). Eloralintide. forum
- What it is: Roche’s weekly dual GLP-1/GIP shot (CT-388 / RO7795068), the Carmot buy. Biased signaling is the science pitch. Not approved. Phase 3 Enith talk started 2026. trial
- How it works: Dual incretin — satiety, slower stomach, glucose-dependent insulin. Not amylin. Not a triple. trial
- Evidence: Phase 1 weekly PK. Phase 2 CT388-103 (n≈469, 48 weeks, five doses 4–24 mg). Phase 2 T2D (CT388-104) ongoing. Phase 3 starting. trial
Stacks
- Mental stack: vs tirz / reta / elo. forum
- Solo in Phase 2. trial
- Planned + petrelintide. trial
Storage notes
- No community mix SOP. Gray “CT-388” is identity theater. forum
Watch for
- “Modestly worse than Zepbound” is analyst Twitter, not your n=1. forum
- Unapproved. Late. forum
- Gray dual-agonist vials are not Roche pens. forum
- GI class: Mild–moderate nausea/vomit/diarrhea. AE discontinuation 5.9% vs 1.3% placebo in the 48-week package. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.